Rare functional variant in TM2D3 is associated with late-onset Alzheimer's disease by Jakobsdottir, Johanna et al.
RESEARCH ARTICLE
Rare Functional Variant in TM2D3 is
Associated with Late-Onset Alzheimer’s
Disease
Johanna Jakobsdottir1☯, Sven J. van der Lee2☯, Joshua C. Bis3☯, Vincent Chouraki4,5☯,
David Li-Kroeger6,7☯, Shinya Yamamoto6,7,8☯, Megan L. Grove9, Adam Naj10,
Maria Vronskaya11, Jose L. Salazar6, Anita L. DeStefano5,12, Jennifer A. Brody3, Albert
V. Smith1,13, Najaf Amin2, Rebecca Sims11, Carla A. Ibrahim-Verbaas2,14, Seung-
Hoan Choi5,12, Claudia L. Satizabal4,5, Oscar L. Lopez15, Alexa Beiser4,5,12, M.
Arfan Ikram2,14,16, Melissa E. Garcia17, Caroline Hayward18,19, Tibor V. Varga20,
Samuli Ripatti21,22, Paul W. Franks20,23,24, Go¨ran Hallmans25, Olov Rolandsson26, Jan-
Håkon Jansson23,27, David J. Porteous19,28, Veikko Salomaa29, Gudny Eiriksdottir1,
Kenneth M. Rice30, Hugo J. Bellen6,7,8,31, Daniel Levy5,32,4, Andre G. Uitterlinden2,33,
Valur Emilsson1,34, Jerome I. Rotter35, Thor Aspelund1,36, Cohorts for Heart and Aging
Research in Genomic Epidemiology consortium¶, Alzheimer’s Disease Genetic
Consortium¶, Genetic and Environmental Risk in Alzheimer’s Disease consortium¶,
Christopher J. O’Donnell5,32, Annette L. Fitzpatrick37,38, Lenore J. Launer17,
Albert Hofman2, Li-San Wang39, Julie Williams11, Gerard D. Schellenberg39,
Eric Boerwinkle9,40‡, Bruce M. Psaty3,37,41,42‡, Sudha Seshadri4,5‡, Joshua
M. Shulman6,7,8‡*, Vilmundur Gudnason1,13‡*, Cornelia M. van Duijn2‡*
1 Icelandic Heart Association, Kopavogur, Iceland, 2 Department of Epidemiology, Erasmus University
Medical Center, Rotterdam, The Netherlands, 3 Cardiovascular Health Research Unit, Department of
Medicine, University of Washington, Seattle, Washington, United States of America, 4 Boston University
School of Medicine, Boston, Massachusetts, United States of America, 5 Framingham Heart Study,
Framingham, Massachusetts, United States of America, 6 Department of Molecular and Human Genetics,
Baylor College of Medicine, Houston, Texas, United States of America, 7 Jan and Dan Duncan Neurological
Research Institute, Texas Children’s Hospital Houston, Texas, United States of America, 8 Program in
Developmental Biology, Baylor College of Medicine, Houston, Texas, United States of America, 9 School of
Public Health, Human Genetics Center, The University of Texas Health Science Center at Houston,
Houston, Texas, United States of America, 10 Department of Biostatistics and Epidemiology, Perelman
School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America,
11 Institute of Psychological Medicine and Clinical Neurosciences, Medical Research Council (MRC) Centre
for Neuropsychiatric Genetics & Genomics, Cardiff University, Cardiff, United Kingdom, 12 Department of
Biostatistics, Boston University School of Public Health, Boston, Massachusetts, United States of America,
13 Faculty of Medicine, University of Iceland, Reykjavik, Iceland, United States of America, 14 Department
of Neurology, Erasmus University Medical Center, CA Rotterdam, The Netherlands, 15 Department of
Neurology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States of America,
16 Departments of Radiology, Erasmus University Medical Center, CA Rotterdam, The Netherlands,
17 Laboratory of Epidemiology and Population Sciences, National Institute on Aging, Bethesda, Maryland,
United States of America, 18 MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine,
University of Edinburgh, Edinburgh, United Kingdom, 19 Generation Scotland, Centre for Genomic and
Experimental Medicine, University of Edinburgh, Edinburgh, United Kingdom, 20 Department of Clinical
Sciences, Genetic and Molecular Epidemiology Unit, Lund University, Malmo¨, Sweden, 21 Institute for
Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland, 22 Department of Public
Health, University of Helsinki, Helsinki, Finland, 23 Department of Public Health & Clinical Medicine, Umeå
University Hospital, Umeå, Sweden, 24 Department of Nutrition, Harvard T.H. Chan School of Public Health,
Boston, Massachusetts, United States of America, 25 Department of Biobank Research, UmeåUniversity,
Umeå, Sweden, 26 Department of Public Health & Clinical Medicine, Section for Family Medicine, Umeå
University, Umeå, Sweden, 27 Research Unit, Skellefteå Hospital, Skellefteå, Sweden, 28 Centre for
Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh,
Edinburgh, United Kingdom, 29 National Institute for Health and Welfare, Helsinki, Finland, 30 Department
of Biostatistics, University of Washington, Seattle, Washington, United States of America, 31 Howard
Hughes Medical Institute, Durham, North Carolina, United States of America, 32 Division of Intramural
PLOS Genetics | DOI:10.1371/journal.pgen.1006327 October 20, 2016 1 / 17
a11111
OPENACCESS
Citation: Jakobsdottir J, van der Lee SJ, Bis JC,
Chouraki V, Li-Kroeger D, Yamamoto S, et al.
(2016) Rare Functional Variant in TM2D3 is
Associated with Late-Onset Alzheimer’s Disease.
PLoS Genet 12(10): e1006327. doi:10.1371/
journal.pgen.1006327
Editor: Jonathan L. Haines, Case Western Reserve
University, UNITED STATES
Received: February 24, 2016
Accepted: August 26, 2016
Published: October 20, 2016
Copyright: This is an open access article, free of all
copyright, and may be freely reproduced,
distributed, transmitted, modified, built upon, or
otherwise used by anyone for any lawful purpose.
The work is made available under the Creative
Commons CC0 public domain dedication.
Data Availability Statement: Summary statistics
(p-values, effect sizes, standard errors, and effect
allele frequencies for all SNPs) for the exome-wide
human genetic analysis are in dbGAP (accession
phs000930). Subset of top results is in the
supporting information. Due to informed-consent
and legal restrictions individual-level genotypes
and phenotypes cannot be shared. All of the
Drosophila data generated as a part of this study
are available in the paper and its Supporting
Information files.
Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland,
United states of America, 33 Department of Internal Medicine, Erasmus University Medical Center, CA
Rotterdam, The Netherlands, 34 Faculty of Pharmaceutical Sciences, University of Iceland, Reykjavik,
Iceland, 35 Institute for Translational Genomics and Population Sciences, Los Angeles BioMedical
Research Institute and Departments of Medicine and Pediatrics, Harbor-UCLA Medical Center, Torrance,
California, United States of America, 36 Centre for Public Health, University of Iceland, Reykjavik, Iceland,
37 Department of Epidemiology, University of Washington, Seattle, Washington, United States of America,
38 Collaborative Health Studies Coordinating Center, Seattle, Washington, United States of America,
39 Department of Pathology and Laboratory of Medicine, Perelman School of Medicine, University of
Pennsylvania, Philadelphia, Pennsylvania, United States of America, 40 Human Genome Sequencing
Center, Baylor College of Medicine, Houston, Texas, United States of America, 41 Department of Health
Services, University of Washington, Seattle, Washington, United States of America, 42 Group Health
Research Institute, Group Health Cooperative, Seattle, Washington, United States of America
☯ These authors contributed equally to this work.
‡ EB and BMP also contributed equally to this work. SS and JMS also contributed equally to this work. VG
and CMvD also contributed equally to this work.
¶ Membership of Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium, Alzheimer’s
Disease Genetic Consortium, and Genetic and Environmental Risk in Alzheimer’s Disease Consortium are
listed in S1 Text.
* Joshua.Shulman@bcm.edu (JMS); villi@hjarta.is (VG); c.vanduijn@erasmusmc.nl (CMvD)
Abstract
We performed an exome-wide association analysis in 1393 late-onset Alzheimer’s disease
(LOAD) cases and 8141 controls from the CHARGE consortium. We found that a rare vari-
ant (P155L) in TM2D3 was enriched in Icelanders (~0.5% versus <0.05% in other Euro-
pean populations). In 433 LOAD cases and 3903 controls from the Icelandic AGES sub-
study, P155L was associated with increased risk and earlier onset of LOAD [odds ratio
(95% CI) = 7.5 (3.5–15.9), p = 6.6x10-9]. Mutation in the Drosophila TM2D3 homolog,
almondex, causes a phenotype similar to loss of Notch/Presenilin signaling. Human
TM2D3 is capable of rescuing these phenotypes, but this activity is abolished by P155L,
establishing it as a functionally damaging allele. Our results establish a rare TM2D3 variant
in association with LOAD susceptibility, and together with prior work suggests possible
links to the β-amyloid cascade.
Author Summary
Alzheimer’s disease (AD) is the most common cause of dementia in the older adult popu-
lation. There is substantial evidence for an important genetic contribution to AD risk.
While prior work has comprehensively evaluated the contribution of common genetic var-
iants in large population-based cohorts, the role of rare variants remains to be defined.
Here, we have used a newer genotyping array to characterize less common variants,
including those likely to impact the function of encoded proteins, in a combined cohort of
1393 AD cases and 8141 control subjects without AD. Our results implicate a novel,
amino acid-changing variant, P155L, in the TM2D3 gene. This variant was discovered to
be more common in the Icelandic population, where it was significantly associated with
both increased risk and earlier age of onset of AD. Lastly, in order to examine the potential
functional impact of the implicated variant, we performed additional studies in the fruit
fly. Our results suggest that P155L causes a loss-of-function in TM2D3, in the context of
TM2D3 and Alzheimer’s Disease
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Notch-Presenilin signal transduction. In sum, we identify a novel, rare TM2D3 variant in
association with AD risk and highlight functional connections with AD-relevant biology.
Introduction
Alzheimer’s disease (AD, [MIM: 104300]), the most common form of dementia, affects more
than 10% of those 65 years and older, increasing to 30% in those 85 years and older [1–4].
Pathologically, AD is characterized by extensive brain neurodegenerative cell loss in association
with extra-cellular β-amyloid plaques and intra-neuronal tangles consisting of hyper-phos-
phorylated tau protein. Multiple mutations in the amyloid-β precursor protein (APP, [MIM:
104760]) and the presenilin-1 and -2 (PSEN1 [MIM: 104311] and PSEN2 [MIM: 600759])
genes cause familial early-onset (<65 years) AD [5,6]. Genome-wide association studies
(GWAS) have also identified numerous common genetic variants of modest effect sizes for
late-onset AD (LOAD, [MIM: 104300]) [7–12]. However, Apolipoprotein E (APOE, [MIM:
107741]) still remains the most important known genetic determinant of LOAD susceptibility
[13,14]. Recently, rare variants with effect sizes similar to the APOE-ε4 allele have also been
identified.While the population-attributable risk of such single rare variants is low, their dis-
coveries may have important implications for understanding diseasemechanisms and develop-
ing novel treatments [15]. Recent examples include a rare protective allele of APP [16] as well
as variants in the novel genes TREM2 [MIM: 605086] [17,18], PLD3 [MIM: 615698] [19],
UNC5C [MIM: 603610] [20], and AKAP9 [MIM:604001] [21]. These findings highlight poten-
tially important, new cellular pathways relevant for disease pathophysiology [15]; for example
TREM2 has spurred intense recent interest in the role of microglia in LOAD [22,23]. Impor-
tantly, because of population histories and demography, rare variants may be population-spe-
cific. The protective APP variant, for example, is found predominantly in Iceland and other
Scandinavian populations [16]. The two variants in AKAP9 have only been reported in Afri-
can-Americans [21], and PLD3 variants appear to vary greatly in frequency between popula-
tions [24].
To date, the identification of rare susceptibility variants in LOAD has been hampered by
poor representation on genotyping arrays used for large GWAS [25]; moreover, direct sequenc-
ing in large numbers of individuals remains costly. Here, using an exome-wide genotyping
array (the Illumina HumanExome Beadchip), we report associations with LOAD in four popu-
lation-based cohorts from the Cohorts for Heart and Aging Research in Genomic Epidemiol-
ogy (CHARGE) consortium [26].
Results
Exome-wide association study of LOAD in CHARGE
The discovery phase of our analysis examined single-variant associations with LOAD. Meta-
analysis was performed across four CHARGE studies including 1393 LOAD cases and 8141
controls (Table 1), using logistic regression-based scores [27,28] and adjusting for age and sex
(seeMethods and Supporting methods in S1 Text). Single-variant results were filtered using
quality control filters that includedminimumminor allele frequency (MAF 0.5%) or minor
allele count (MAC 5) in cases (see alsoMethods) resulting in 52026 total variants tested.
Given the rarity of many variants captured on the exome array, we additionally performed
association analysis, where we considered rare variants from the same gene in aggregate. For
this complementary analysis we used the Sequence Kernel Association Test (SKAT) test [29], a
TM2D3 and Alzheimer’s Disease
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variance component score test for the association of a set of multiple variants with a trait.
SKAT tests the null hypothesis of no variation of effects and therefore the statistical model of
SKAT is applicable to test association of variant sets that may have a combination of variants
including both risk and protective alleles or those with no effect. Variants were included in the
SKAT analysis based on functional annotation (seeMethods) and maximum frequency of 5%.
Because the SKAT results were filtered by cumulative set-basedMAF and MAC, considering
all variants in aggregate, and not by minimumMAF of single SNPs (seeMethods), this com-
plementary analysis includedmany variants that did not meet the criteria for inclusion in the
single-variant tests. The results of both the single-variant and SKAT discovery analysis are pre-
sented in S1 Table and quantile-quantile plots are in S1 Fig. Below, we discuss each of the top
three results, our efforts to replicate the novel loci in independent cohorts, and for TM2D3,
subsequent functional validation of the implicated variant inDrosophila.
APOE
As expected based on many prior LOAD GWAS [12], three common intronic variants near
APOE reached the Bonferroni threshold of exome-wide significance (p< = 9.6x10-7) in the sin-
gle-variant analysis: rs769449 in APOE (p = 5.8x10-38, MAFcase = 17%, MAFcontrol = 10%),
rs2075650 in TOMM40 (p = 1.2x10-24, MAFcase = 18%, MAFcontrol = 13%), and rs6859 in
PVRL2 (p = 1.5x10-9, MAFcase = 46%, MAFcontrol = 40%). AlthoughAPOE is a well-established
LOAD risk locus it did not achieve nominal significance in the SKAT analysis, possible because
the established common risk variants at this locus exceed our frequency threshold for consider-
ation in the SKAT analysis (MAF<0.05) (S2 Table).
SKAP2
rs17154402 in SKAP2 (MIM: 605215) on chromosome 7p15 also showed a significant associa-
tion with LOAD (p = 2.1x10-7, MAFcase = 0.22%, MAFcontrol = 0%). This SNP is predicted to
introduce a non-synonymous amino acid change (S253T in the longer isoform) in the SKAP2
protein. The SKAP2 locus also achieved significant association with LOAD (p = 4.5x10-7) in
the SKAT analysis. Although the SKAT analysis included three distinct SKAP2missense alleles,
the SKAT result was fully explained by the variant identified in the single-variant analysis (S2
Table). rs17154402 was not significantly associated with LOAD risk in the ADGC or GERAD
cohorts, which are 2 large European-ancestry case-control datasets (13 carriers in 8256 controls
[MAF 0.08%] and 9 carriers in 13333 cases [MAF 0.03%], p = 0.05), and compared to the dis-
covery CHARGE cohort, showed an opposite direction of effect in these samples. We noted
that rs17154402 has a higher frequency in persons of African compared to European ancestry
(MAF~7% in Yorubans and 3% in all African populations combined in the 1000 Genomes
Table 1. Sample characteristics of discovery cohorts.
AGES FHS CHS RS
Characteristics Controls Cases Controls Cases Controls Cases Controls Cases
Study Design Population-based cohort Population-based cohort Population-based cohort Population-based cohort
No. participants 2374 143 1338 230 2013 557 2416 463
Women, No (%) 1401 (59) 85 (59) 754 (56) 158 (69) 1134 (56) 343 (62) 1227(51) 319(69)
Age, mean (SD), year 78.89 (4.98) 82.50 (4.94) 79.84 (8.57) 85.06 (6.90) 81.18 (5.15) 82.1 (5.32) 78.2(7.71) 83.3(6.59)
APOE ε4+, No. (%) 638 (27) 66 (46) 258 (20) 74 (32) 397 (20) 176 (32) 609(26) 190(43)
AGES: Age, Gene/Environment Susceptibility study, FHS: Framingham Heart Study, CHS: Cardiovascular Health Study, RS: Rotterdam Study.
doi:10.1371/journal.pgen.1006327.t001
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Project data, and Grove et al [30] reported a ~5%MAF in African populations versus 0.22% in
European ancestry subjects).We therefore took advantage of an available African-American
subsample of the CHARGE CHS cohort for attempted replication. However, the variant again
showed an inconsistent direction of effect and non-significant association (93 [12 carriers]
cases, 208 [33 carriers] controls; p = 0.66). Based on the non-replication of SKAP2 in available
independent datasets, it was not pursued further.
TM2D3
Our discovery analysis also identified rs139709573, a missense variant in TM2D3 (MIM:
610014) on chromosome 15q26. Although the association statistic did not exceed the Bonfer-
roni threshold for exome-wide significance in the CHARGE discovery analysis (single-variant
p = 2.0x10-6, SKAT p = 8.3x10-6), several important observations led us to consider this variant
further. First, we noted that while very rare (0–0.06%MAF in European ancestry populations
(S3 Table)) the TM2D3 variant was enriched nearly 10-fold in the Icelandic AGES cohort
(0.45%MAF). Second, rs139709573 was significantly associated (p = 5.9x10-8, Table 2) with
LOAD when the analysis was restricted to the AGES-discovery sample (143 cases, 2374 con-
trols). Third, prior experimental studies potentially link TM2D3 to AD-relevant biology. Spe-
cifically, TM2D3 shares homologywith the β-amyloid peptide binding protein (BBP or
TM2D1) [31], and as discussed further below, genetic studies of the conservedDrosophila
ortholog almondex (amx) strongly suggest links to γ-secretase function [32].
In the SKAT analysis, the association of TM2D3with LOAD was fully accounted for by
rs139709573; although, 3 other variants were considered in this analysis (S2 Table). In the sub-
sequent analyses and functional follow-up, we therefore restricted our focus on rs139709573.
First we evaluated potential inflation in the test statistic of the TM2D3 rs139709573 result in
the AGES-discovery cohort (Supporting results in S1 Text) and we further confirmed the
genotypes of risk allele carriers by re-genotyping them with a TaqMan assay. We next directly
genotyped rs139709573 in an independent Icelandic AGES-followup cohort (290 cases, 1529
controls), consisting of individuals who had not been genotyped previously with the exome
array. The rs139709573 association was also detected in this sample (p = 3.1x10-3, Table 2). As
Table 2. Sample characteristics and association results for P155L (rs139709573) in TM2D3 in the two Icelandic AGES cohorts.
Cohort Group No(%
women)
Age, mean (SD),
year
APOE ε4+ No
(%)
TM2D3 carriers, No
(%)
p (OR, 95% CI)a pFisher’s
Exact
b
pconditionalc
AGES-
discovery
Cases 143 (59) 82.5 (4.9) 66 (46) 7 (4.9) 5.9x10-8 (8.62, 3.43–
21.68)
5.6x10-4 8.4x10-8
Controls 2374 (59) 78.9 (5.0) 638 (27) 20 (0.8) . . . . . . . . .
AGES-
followup
Cases 290 (59) 84.5 (5.1) 127 (44) 6 (2.1) 3.0x10-3 (5.42, 1.60–
18.32)
6.2x10-3 1.1x10-2
Controls 1529 (57) 79.4 (5.3) 396 (26) 6 (0.4) . . . . . . . . .
Pooledd Cases 433 (59) 83.9 (5.2) 193 (45) 13 (3.0) 6.6x10-9 (7.45, 3.49–
15.90)
5.9x10-5 6.8x10-8
Controls 3903 (58) 79.1 (5.1) 1034 (26) 26 (0.7) . . . . . . . . .
All p-values are based on the 2-sided alternative.
a Score tests adjusted for age and sex based on a logistic regression model. The unconditional MLE of the OR is reported based on fitting the full model
including the SNP. Note, that those point estimates of OR could be inflated (Supporting results in S1 Text)
b P-value from the Fisher’s exact test for carrier status. For the meta-analysis the data were pooled.
c P-value conditional on APOE ε4 carrier status. Based on a score test after adjusting for age, sex, and APOE ε4.
d The two cohorts are pooled in a stratified analysis (stratified by cohort).
doi:10.1371/journal.pgen.1006327.t002
TM2D3 and Alzheimer’s Disease
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expected, an analysis combining all of the AGES data on TM2D3 demonstrated an enhanced
association of the TM2D3 variant with LOAD (OR = 7.45; 95% CI 3.49–15.90; p = 6.6x10-9).
We also observed an association with age-at-onset in the AGES cohorts (hazard ratio = 5.3;
95% CI 2.7–10.5; p = 1.1x10-6, see also non-parametric Kaplan-Meier curves in Fig 1). Using
the PHASE program [33–35] we estimated that rs139709573 resides on a single haplotype in
the Icelandic population (Supporting results in S1 Text), and we further excluded potential
confounding due to cryptic relatedness (Supporting results in S1 Text). Similarly, the associa-
tion between rs139709573 and LOAD was robust to adjustment for APOE genotype (Table 2).
Given the low frequency of rs139709573 in individuals of European ancestry, there were lim-
ited numbers of carriers in GERAD and ADGC (11 carriers in 13333 cases [0.041%MAF]; 4
carriers in 8256 controls [0.024%MAF]).While, the association was not statistically significant
(p = 0.4), the direction of effect was consistent with that observed in AGES (OR = 1.7, 95% CI
0.5–7.3).
Analysis of TM2D3 transcripts and expression
The TM2D3 gene has several alternatively spliced transcripts, including six protein-coding
transcripts [36]. rs139709573 falls within an exon common to all six isoforms (S2 Fig) and
causes a Proline to Leucine amino acid change (P155L in the longest isoform). Gene and tran-
script expression estimates were extracted from publically available Genotype-Tissue Expres-
sion consortium (GTEx) data [37], estimated as “transcripts per million” (TPM), using the Toil
workflow [38] in the UCSC Xena browser (http://xena.ucsc.edu/).TM2D3 is expressed in all
GTEx tissues, including frommany brain regions (S3 Fig). The GTEx expression data further
Fig 1. Kaplan-Meier survival curves for TM2D3. Curves are based on incident data only. There was no
evidence of bias due to competing risk of death (Supporting results in S1 Text).
doi:10.1371/journal.pgen.1006327.g001
TM2D3 and Alzheimer’s Disease
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show that the alternative TM2D3 transcripts are similarly expressed across diverse human tis-
sues (S4 Fig).
Structure of TM2D3 protein
TM2D3 encodes a predicted double-pass transmembrane protein with evidence of evolutionary
conservation (Fig 2A). The variant falls within the overall well-conservedC-Type Lectin
domain and is adjacent to other invariant residues in the first predicted extracellular domain
[32] (Fig 2B). While P155L is not predicted to be strongly damaging by PolyPhen [39], SIFT
[40], or CADD (C-Score = 7.3) [41] and cross-species alignments show that the Proline residue
is not conserved (Fig 2A), the two amino-acids do have important property differences, consis-
tent with a potentially non-conservative substitution. Proline, the only cyclic amino-acid, fre-
quently resides on the surface of folded proteins, and can underlie structural “kinks” or bends.
Proline is unique in its inability to form hydrogen bonds that stabilize alpha-helices and beta-
sheets. By contrast with Proline, Leucine favors alpha-helical secondary structure, and is more
commonly buried in the interior of folded protein structures [42].
Functional validation of TM2D3 (P155L) in Drosophila
In order to investigate the potential functional consequences of P155L and its possible link to
AD, we turned to the fruit fly, Drosophila melanogaster. Human TM2D3 and the homologous
fly gene, amx, are 51% identical and 64% similar (Fig 2A). Mutations in amx cause a strong
maternal effect neurogenic phenotype, characteristic of defective Notch signaling, and lead to
embryonic lethality (Fig 3A and 3B) [43,44]. Similar to the cleavage of APP to generate the
pathogenic ß-amyloid peptide, Notch receptor signaling requires homologous cleavage by γ-
secretase for receptor activation. In Drosophila, loss of Notch or its regulators (e.g. presenilin)
cause similar neurogenic phenotypes, due to impaired lateral inhibition and the inappropriate
differentiation of ectodermal tissue toward a neural fate [45–47]. Moreover, prior genetic epis-
tasis experiments suggest that amxmay function at the γ-secretase cleavage step [32].
To determine whether TM2D3 and amx have conservedmolecular functions, we “human-
ized” theDrosophila amx gene by replacing its coding sequence with that of human TM2D3 in
the context of a genomic rescue construct (Fig 3C). Following establishment of stable trans-
genic lines, this construct was crossed into an amxmutant genetic background (amx1/Df(1)
Exel9049). Consistent with prior reports [43,44], when crossed to amxmutant males, all
embryos laid by amxmutant females exhibited a strong neurogenic phenotype, failing to hatch
from their eggs (Fig 3B and 3D). This embryonic defect and the resulting female sterility can
be fully rescued by a genomic rescue construct with the wild-type (+) fly amx gene (Fig 3D
and 3E). Due to the lethality of Df(1)Exel9049/Yhemizygousmale progeny, complete rescue of
the amx phenotype is predicted to lead to a maximum of ~75% egg hatching based on Mende-
lian expectations (Fig 3D, S5 Fig). Introduction of wild-type human TM2D3, under control of
endogenous amx regulatory sequences, demonstrated significant rescue activity compared to
amxmutant females (34.2% vs. 0% egg hatching p<0.001). Overall, based on the egg hatching
assay (Fig 3D), the activity of the human TM2D3 construct was estimated to be roughly half
that observed for fly amx. Consistent with this, we observed a range in the severity of the neu-
rogenic phenotype severity (S6 Fig), including embryos exhibiting a complete rescue (Fig 3G)
and producing viable progeny that can develop into adult flies with no obvious morphological
phenotypes. By contrast, an otherwise identical TM2D3P155L genomic construct, but harboring
the AD-associated P155L variant, was unable to rescue the neurogenic phenotype (Fig 3H) or
the associated female sterility (Fig 3D). No animals hatched out of more than 900 eggs laid
from TM2D3P155L female flies. Consistent results were also seen in complementary assessments
TM2D3 and Alzheimer’s Disease
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of rescue activity for the amx peripheral nervous system neurogenic phenotype (S6 Fig). In
sum, our results demonstrate that human TM2D3 can functionally substitute for fly amx in the
context of embryonic Notch signaling, and that the P155L variant causes a loss-of-function in
this context.
Discussion
We identified a novel LOAD-associated gene, TM2D3, harboring a rare missensemutation
(P155L) that is associated with increased risk and earlier onset of LOAD diagnosis in an Icelan-
dic population. Our experiments inDrosophila further suggest that this LOAD-associated
P155L variant leads to a loss-of-function of TM2D3 in the context of Notch signaling during
embryogenesis.While we could neither confirm nor negate the TM2D3 finding in available
European ancestry populations–possibly because of the low P155L allele frequency, a consis-
tent association was demonstrated in an Icelandic cohort. Although the TM2D3 variant failed
to achieve the Bonferroni significance threshold in our CHARGE-wide meta-analysis our
observation of increased frequency and enhanced association within the Icelandic AGES-dis-
covery cohort highlighted the TM2D3 variant for further consideration. Significant association
in the AGES-followup sample coupled with variant functional validation inDrosophila sug-
gests a role for TM2D3 in AD susceptibility. Our investigation thus exemplifies the importance
not only for statistical rigor and transparency, but also flexibility in study design, when per-
forming rare variant genetic association studies, in particularwhen statistical results are
accompanied by relevant functional experiments.
TM2D3 has not previously been directly linked to AD. The encoded protein is predicted to
contain two transmembrane regions, and additional domains with homology to C-Type lectins
and G-protein coupled receptors (DRF motif) (Fig 2B). Since the P155L variant resides within
the well-conservedC-Type lectin domain, the variant could plausibly disrupt the interaction of
TM2D3 with a putative glycosylated binding partner. Alternatively, as suggested above, distinct
structural properties of Leucine versus Proline may disrupt protein folding [42]. Interestingly,
TM2D3 shares homology with the β-amyloid peptide binding protein (BBP or TM2D1), which
avidly binds to and sensitizes cells to toxicity caused by the β-amyloid peptide [31]. However,
overexpression of TM2D3 (referred to as BLP2 in Kajkowski et al. [31]) was not associated
with similar toxicity in cell culture. In mammals, TM2D3 it is highly expressed in the brain,
including in the hippocampus, hypothalamus, and amygdala, potentially consistent with a role
in AD pathogenesis (http://biogps.org/#goto=genereport&id=80213 and S3 Fig) [31,48,49].
Additionally, micro-array analysis suggests that the expression of TM2D3 is down-regulated in
the hippocampus of AD cases compared to controls [50].
While incompletely studied in mammals, loss-of-functionmutants in the well-conserved
Drosophila homolog of TM2D3, amx, cause embryonic phenotypes associated with disruptions
in Notch signaling [51]. Further, genetic epistasis experiments support a potential role for amx
in Notch receptor intramembranous proteolysis [32], a process that is mediated by the preseni-
lin/γ-secretase complex. One speculative hypothesis is that TM2D3/Amx participates either
directly or indirectly in the intramembranous cleavage of Notch as well as in the homologous
proteolytic processing of APP by γ-secretase. In this model, the P155L variant might potentially
influence the generation of toxic β-amyloid peptides, similar to well-established disease suscep-
tibility variants in APP, PSEN1, and PSEN2 [52].
Fig 2. Sequence alignment and domain structure of TM2D3. (A) Sequence alignment of TM2D3 homologs shows overall strong
conservation but lack of conservation for P155L. Sequence alignment of human (TM2D3), mouse (Tm2d3), zebrafish (tm2d3),
Drosophila (amx) and C. elegans (C41D11.9) using Clustal X2.1 is shown. The conserved amino acids are highlighted according to the
standard color scheme of Clustal X. (B) Primary sequence and schematic diagram of the domain structure of human TM2D3.
doi:10.1371/journal.pgen.1006327.g002
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Taking advantage of the potential functional conservation, we found that human TM2D3
expressed under the control of endogenousDrosophila amx regulatory elements is capable of
rescuing the embryonic neurogenic phenotype, indicating that Amx and TM2D3 are orthologs
and have conservedmolecular functions in vivo. Importantly, we found that introduction of
the LOAD-associated P155L variant into an otherwise identical TM2D3 genomic rescue con-
struct abolishes the rescue activity. This result is consistent with either a partial or complete
loss-of-functionmechanism of the P155L variant, albeit within the heterologous context of
Notch signaling in theDrosophila embryo. It is notable that the P155L variant was neither
well-conservednor predicted by bioinformatics as damaging; nevertheless, our cross-species
approach convincingly demonstrates its functional impact. Our overall strategy of first rescu-
ing the loss-of-function phenotype of the predicted homologous gene in flies, followed by
examining the potential consequences of an implicated variant can be a powerful approach for
the follow-up of many similar findings emerging from human genomic studies, including oth-
ers using exome genotyping arrays or next generation sequencing approaches [53,54].
In summary, we have identified a missense mutation in the TM2D3 gene with a strong
impact on LOAD risk. The TM2D3 variant is enriched ~10-fold and associated with both risk
and age-at-onset of LOAD in the Icelandic population.We further show that P155L is associ-
ated with a loss-of-function in the heterologous but potentially relevant context of Notch sig-
naling inDrosophila embryos.We therefore speculate that TM2D3 may participate in the
proteolytic processing of both Notch and APP, linking it to the amyloid cascade like other
well-established AD susceptibility variants. Although we have demonstrated an association of
the TM2D3 variant only in the Icelandic population, our findingsmay thus have broader impli-
cations for understanding LOAD.
Methods
Studies and participants
Four studies from the CHARGE consortium genotyped a total of 1393 AD cases and 8141 cog-
nitively intact controls for an ExomeChip (EC) genotyping array. All participants in the discov-
ery phase of the analysis were of European or European American descent (Table 1). In the
follow-up analysis we included Icelandic individuals from the AGES-followup cohort, African-
American participants of the CardiovascularHealth Study (CHS), and European or European
American individuals from the Alzheimer’s Disease Genetics Consortium (ADGC) and
Fig 3. TM2D3P155L is a loss-of-function allele. (A-B) Embryos laid by amx mutant females exhibit a strong
neurogenic phenotype. (A) Lateral view of a late stage control embryo shows properly patterned and
organized central and peripheral nervous system structures. (B) Embryos laid by amx mutant females show
dramatic increase in the number of neurons, labeled by Elav (neuronal nucleus, green) and Hrp (neuronal
membrane, magenta). (C) Schematic diagram of the amx locus and genomic rescue constructs generated
for this study. amx1 contains an 8 nucleotide deletion that introduces a frameshift followed by a stop codon
after residue 184 (Michellod and Randsholt, 2008). Df(1)Exel9049 is a molecularly defined deletion that
covers amx and two neighboring genes. The genomic rescue construct contains a ~3.3 kb fragment that can
fully rescue the sterility of amx1/Df(1)Exel9049 mutant females and the neurogenic defects seen in the
progeny (A, E). Coding region of Amx has been replaced by TM2D3 to “humanize” the fly amx gene. (D) Egg
hatching assay reveals that hTM2D3[+] can partially suppress the female sterility of amx1/Df(1)Exel9049
mutant females, while hTM2D3[P155L] cannot. Due to the lethality of Df(1)Exel9049/Y hemizygous male
progeny, complete rescue of the amx phenotype is expected to lead to a maximum of ~75% egg hatching, as
denoted by the Mendelian Expectation line (also see S3 Fig). (E-H) The developing nervous system is shown
for embryos laid by amx mutant females with and without amx[+], TM2D3[+], and TM2D3[P155L] genomic
rescue constructs. TM2D3[+] is capable of complete rescue of the amx neurogenic phenotype in some
embryos (G), whereas all embryos with the hTM2D3[P155L] construct exhibit strong neurogenic phenotypes
(H). Also see S5 Fig for assessment of rescue of the amx peripheral nervous system neurogenic phenotype.
Scale bars = 100μm.
doi:10.1371/journal.pgen.1006327.g003
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Genetic and Environmental Risk in Alzheimer’s Disease consortium (GERAD). Further details
on phenotyping and other cohort characteristics are in the Supporting methods in S1 Text.
Ethics statement
All participants provided informed consent and all studies were approved by their respective
ethics committees.
Genotyping
All four CHARGE cohorts were genotyped for the HumanExome BeadChip v1.0 from Illumina
(San Diego, CA, USA). Genotype calling and quality control was performed centrally as
describedpreviously [30]. Each study also performed quality control locally (Supporting
methods in S1 Text). Post-analysis quality control on the top results included visual inspection
of cluster plots (S1 Fig) and re-genotyping of TM2D3 carriers using a TaqMan assay (genotype
calls were 100% validated). TM2D3 variant was genotyped in the AGES-followup cohort using
the TaqMan assay. In ADGC and GERAD consortia the SKAP2 and TM2D3 variants were gen-
toyped on the Illumina HumanExome BeadChip v1.0 or v1.1 from Illumina (Supporting
methods in S1 Text).
Statistical analysis
Statisticalmethods of the discoveryphase. In the discovery phase of our analysis we used
score tests [27] for the single-variant analysis and the SequenceKernel Association Test (SKAT
[29]) to test for the aggregate effect of multiple low-frequency variants within a gene on
LOAD. Each study adjusted for age, sex, and for those principal components associated with
LOAD (see Supporting methods in S1 Text). The discovery analysis was not adjusted for
APOE genotypes; however this important LOAD risk factor was considered in secondary anal-
yses of top findings. Both tests were performed in R with the seqMeta package (http://cran.r-
project.org/web/packages/seqMeta/) to meta-analyze study-specific scores and respective vari-
ances and covariances (see details in Supporting methods in S1 Text) [28]. In the single-vari-
ant analysis we included variants present in at least two studies, variants with a minor allele
frequency (MAF) 0.5% or assuming that rare damaging alleles could be prevalent predomi-
nantly in cases we also included variants with minor allele count (MAC) 5 in cases. This
resulted in 52,026 single-variant tests. In the SKAT analysis we grouped the variants by genes
using the start and stop positions as annotated by dbNSFP v2.0 [55] to define gene boundaries.
We included only variants of MAF< 5% in the combined sample, and further annotated as
missense, stop-gain, stop-loss, or splice-site variants. Then we required that genes have at least
two such variants as well as at least two studies having a polymorphic variant. This resulted in
11,303 SKAT tests. After filtering, the Bonferroni correction thresholds that accounted for mul-
tiple testing were 9.6x10-7 for single-variant tests and 4.4x10-6 for SKAT. Two analysts inde-
pendently performed the meta-analysis, leading to identical results.
Statisticalmethods in follow-up analysis of TM2D3 in AGES. We used a score test and
Fisher’s exact test for the follow-up analysis based on an independent Icelandic AGES sample
(AGES-followup). We report (Table 2) estimates of the ORs based on fitting the full model
(AD ~ age + sex + TM2D3) instead of the one-step approximation used in seqMeta (see Sup-
portingMethods in S1 Text for details). For the AGES-discovery cohort we similarly update
and report estimates of the ORs (Table 2) based on fitting the full model (S1A Table, S2
Table). In the AGES study, we also used a mixed-model to account for potential confounding
effect relatedness might have on the association of P155L in TM2D3with LOAD (Supporting
results in S1 Text). Cox regression was used to test for association of P155L with age-at-onset
TM2D3 and Alzheimer’s Disease
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in the AGES data after adjusting for sex and APOE genotype. Individuals with LOAD diagnosis
at the baseline visit were excluded so only at-risk individuals were included in the analysis. As
detailed in the Supporting methods in S1 Text, the survival analysis accounted for left-trunca-
tion (i.e. follow-up begins after 65 years) and right-censoring (i.e. censoring that happens if a
participant is lost to follow-up before having an event).
Drosophila
Detailedmethods for ourDrosophila experiments can be found in the Supporting methods in
S1 Text. Briefly, the rescue activity of amx, TM2D3, or TM2D3P155L genomic constructs was
examined in female flies of the genotype amx1/Df(1)Exel9049; {Rescue Trangene}/+ or amx1/Df
(1)Exel9049; {Rescue Trangene} when crossed to amx1males (with or without the {Rescue
Transgene})[43]. To visualize the developing nervous system, resulting embryos were stained
with anti-Hrp (1:1000) [56], a neuronal membrane marker and anti-ELAV (1:100) [57], a neu-
ronal nuclear marker. For egg hatching, adults were allowed to lay eggs for 5 hours on grape
juice agar plates, and larvae were counted 24 hours later.
Supporting Information
S1 Text. Supporting results andmethods.Four supporting results sections and seven sup-
portingmethods sections, and sections with collaborators, and detailed funding information.
(PDF)
S1 Fig. Quantile-quantile and cluster plots. Top row Quantile-quantile plots for the exome-
wide discoverymeta-analysis. Known genes are in orange. The genomic control coefficient
(λGC) is reported.Middle panel: Variants near APOE excluded Bottom row Cluster plots for
SNPs in SKAP2 and TM2D3 demonstrate appropriate calling of the rare variant genotypes.
(PDF)
S2 Fig. Schematic of TM2D3 transcripts.A schematic of TM2D3 transcripts. Ensembl identi-
fiers (amino acid change due to rs13970957 in parenthesis) are marked by the schematic of
each protein-coding transcripts. Bold text highlights transcripts that are also in RefSeq. The
exon that contains rs13970957 is marked with an arrow. The schematic was retrieved 27 May
2016 from the Ensembl browser.
(PDF)
S3 Fig. Expression of TM2D3 in GTEx samples.Overall gene expression in various tissues,
brain tissues are in yellow. TPM (“transcripts per million”) estimated using RSEM [58] on the
GTEx data [37] (retrieved 26 May 2016 from UCSC Xena browser).
(PDF)
S4 Fig. Expression of TM2D3 protein-coding transcripts in GTEx tissues.Expression of pro-
tein-coding transcripts in all tissues (excluding blood), all brain tissues, and hippocampus only.
TPM (“transcripts per million) estimated using kallisto [59] on the GTEx data [37] (retrieved
26 May 2016 from UCSC Xena browser). Transcript ENST00000559107 was not included in
the plots because it is very lowly expressed and visualization was better without it.
(PDF)
S5 Fig. Experimental crossing scheme for rescue experiments.The general crossing scheme
is shown for the egg hatching rescue, quantified in Fig 2D. Due to the lethality of Df(1)
Exel9049/Yhemizygousmale progeny, complete rescue of the amx neurogenic phenotype is
expected to lead to a maximum of ~75% egg hatching.
(TIFF)
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S6 Fig. Neurogenic phenotypes in developing flies.TM2D3[+] but not TM2D3[P155L] can
suppress the neurogenic phenotype in the developing fly embryonic peripheral nervous system
(PNS). (A-B) Maternal effect neurogenic defects in amxmutants can also be seen in the PNS.
Compared to control embryos (A), maternal amxmutant embryos (B) show increased number
of SensoryOrgan Precursor cells (SOPs), labeled by Senseless (Sens, red), due to defective lat-
eral inhibition. Embryos are counterstained with DAPI (blue). (C-F) PNS phenotypes in
embryos laid by amxmutant females with or without amx[+], TM2D3[+], and TM2D3[P155L]
genomic rescue constructs. Thoracic segments (T1, T2, T3) of stage 11 embryos are shown.
TM2D3[+] can rescue the lateral inhibition defects in SOPs in some (Compare C, D and E) but
not all embryos (E’). In contrast, all embryos from amxmutant females with TM2D3[P155L]
exhibit neurogenic PNS phenotypes (F, F’). Scale bars = 100μm for A-B, = 50μm for C-F.
(TIFF)
S1 Table. Results of exome-widediscovery analysis.Top results of exome-wide single variant
(A) and SKAT (B) discovery analysis. Complete results areavailable in dbGAP (accession
phs000930). A: Direction = AGES-CHS-FHS-RS, Alleles = non-coding/coding,AF displayed
as percentage (%). B: cumAF = cumulative allele frequency displayed as percentage (%),
N_SNPs = number of SNPs in test.
(PDF)
S2 Table. Variant- and study-specificbreak-downof TM2D3, SKAP2, and APOE results.
(PDF)
S3 Table. Allele frequencyof P155L in populations of European ancestry.
(PDF)
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